Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. (XNCR) is a clinical-stage biopharmaceutical leader pioneering engineered antibody therapeutics for cancer and autoimmune diseases through its proprietary XmAb® technology platform. This page serves as the definitive source for tracking Xencor's latest developments, providing investors and industry observers with timely updates on scientific advancements and business milestones.
Access comprehensive coverage of Xencor's clinical trial progress, regulatory updates, and strategic collaborations with global pharmaceutical partners. Our curated news collection features verified press releases and analysis-worthy developments including technology licensing agreements, pipeline expansions, and research breakthroughs in antibody engineering.
Key content focuses include updates on XmAb® platform innovations, partnership announcements with major drug developers, clinical study results for novel cancer treatments, and progress in autoimmune therapy candidates. All content is rigorously vetted to ensure relevance to investment decision-making and scientific credibility.
Bookmark this page for streamlined access to Xencor's evolving story in biotherapeutic innovation. Check regularly for critical updates on therapeutic candidates moving through clinical development phases and new applications of its protein engineering expertise.
Xencor, Inc. (NASDAQ:XNCR) announced positive results from its Phase 1 trial of vudalimab, a PD-1 x CTLA-4 bispecific antibody, aimed at treating advanced solid tumors. The study, presented at the SITC meeting, showed vudalimab was generally well-tolerated with an objective response rate of 14.1%. Partial responses were noted in various cancers, including two in castration-resistant prostate cancer (CRPC). A complete response occurred in a patient with BRCA1+ ovarian cancer. Xencor plans to initiate Phase 2 studies for metastatic CRPC and advanced pelvic tumors.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, reported its third-quarter financials for 2021, revealing total revenue of $19.7 million, down from $35.4 million in 2020. The net loss widened to $40.2 million or $(0.69) per share, compared to a loss of $12.6 million or $(0.22) per share last year. Key developments include positive initial data from the Phase 1 study of XmAb306 and plans for upcoming presentations at major conferences. Looking ahead, Xencor expects to end 2021 with $575-$625 million in cash, supporting operations into 2025.
Xencor, Inc. (NASDAQ: XNCR) announced updated clinical data from its Phase 1 study of plamotamab, a bispecific antibody for treating B-cell malignancies, to be presented at the ASH Annual Meeting on December 12, 2021. The drug showed encouraging activity with an overall response rate (ORR) of 38.2% in diffuse large B-cell lymphoma and 80% in follicular lymphoma. Cytokine release syndrome was common but manageable. The company plans to initiate studies combining plamotamab with chemotherapy-free treatments starting late 2021 or early 2022.
Xencor, Inc. (NASDAQ:XNCR) announced updated results from its Phase 1 study of tidutamab, a bispecific antibody targeting neuroendocrine tumors (NETs). The study reported a recommended dosing regimen of 0.3 mcg/kg priming dose followed by 1.0 mcg/kg. At the data cut-off in August 2021, 41 patients were treated, with a 27% disease control rate. Tidutamab was well tolerated, with a low incidence of severe adverse effects. The drug is moving to a Phase 1b/2 study for Merkel cell carcinoma and small cell lung cancer, indicating potential advancements in treatment options.
Xencor, Inc. (NASDAQ:XNCR), a biopharmaceutical company specializing in engineered monoclonal antibodies and cytokines, has announced its participation in two investor conferences. The Credit Suisse 30th Annual Healthcare Conference will feature a presentation on November 9 at 2:40 p.m. ET. Additionally, the Jefferies London Healthcare Conference will have an on-demand presentation available starting November 18 at 8:00 a.m. GMT. Webcasts will be accessible on the company's website, with replays archived for at least 30 days.
Xencor, Inc. (NASDAQ: XNCR) will release its third quarter 2021 financial results after market close on November 8, 2021. The management will conduct a webcast and conference call at 4:30 p.m. ET to discuss results and provide a corporate update. Investors can access the call by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers. The call will also be available via a live webcast on their website, archived for 30 days.
Xencor has entered a second collaboration with Janssen Biotech to develop plamotamab, a bispecific antibody targeting CD20 x CD3 for B-cell malignancies. The deal includes a
Xencor, Inc. (NASDAQ:XNCR) announced five poster presentations at the Society for Immunotherapy of Cancer's annual meeting from November 10-14, 2021. Key topics include clinical results for vudalimab, a PD-1 x CTLA-4 bispecific antibody, in various cancers, and data on preclinical programs targeting IL-12, PD-L1, TGFβR2, and NK cell engagement. The company aims to advance its dual checkpoint therapy in Phase 2 trials for advanced prostate cancer and gynecologic malignancies, indicating potential growth in its oncology pipeline.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines, will present at the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 4:00 p.m. ET. The event will be available via live webcast in the Investors section of their website. Xencor is currently developing 22 clinical candidates using its XmAb® technology, which enhances protein structure for innovative therapeutic actions. A replay of the presentation will be accessible for 30 days post-event.
Xencor, a clinical-stage biopharmaceutical company, reported significant financial results for Q2 2021, with total revenue soaring to $67.4 million, up from $13.1 million year-on-year. The company initiated a Phase 2 study for XmAb717 in metastatic prostate cancer and plans further studies for other drug candidates. R&D expenses increased to $49.5 million, reflecting ongoing development efforts. Xencor achieved a net income of $52.2 million, a turnaround from a net loss of $35 million in Q2 2020. The company aims to maintain cash reserves between $475 million and $500 million by year-end.
